ORAL ABSTRACT: CML-652: ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients With Previously Treated CP-CML
Year: 2026
Type: article
Authors: Fadi G Haddad, Dennis Dong Hwan Kim, Fabian Lang, Michael Mauro, Dong-Wook Kim, Susan Saussele, Philipp le Coutre, Michael C Heinrich, Sarah Altmeyer, Naranie Shanmuganathan, Elvira Mora Castera, Raquel de Paz Arias, Koji Sasaki, Franck E Nicolini, Valerie Coiteux, Dragana Milojkovic, Gabriel Etienne, Nicole Blijlevens, Yingsi Yang, Qi Wang, Brianna Hoffner, M Damiette Smit, Andreas Hochhaus
Institutions: The University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Centre, Eulji University Uijeongbu Eulji Medical Center, University Hospital Frankfurt, Memorial Sloan Kettering Cancer Center, Heidelberg University, Medizinische Fakultät Mannheim, Charité – Universitätsmedizin Berlin, OHSU Knight Cancer Institute, Universitätsklinikum des Saarlandes, Royal Adelaide Hospital, Hospital Universitari i Politècnic La Fe, Hospital Universitario La Paz, Inserm, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Hammersmith Hospital, Institut Bergonié, Radboud University Medical Center, Jena University Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204686268